<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Kazan medical journal</journal-id><journal-title-group><journal-title xml:lang="en">Kazan medical journal</journal-title><trans-title-group xml:lang="ru"><trans-title>Казанский медицинский журнал</trans-title></trans-title-group></journal-title-group><issn publication-format="print">0368-4814</issn><issn publication-format="electronic">2587-9359</issn><publisher><publisher-name xml:lang="en">Eco-Vector</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">611074</article-id><article-id pub-id-type="doi">10.17816/KMJ611074</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>Experimental medicine</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>Экспериментальная медицина</subject></subj-group><subj-group subj-group-type="article-type"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title xml:lang="en">Activity of enzymes destroying extracellular nucleotides in the tissues of rats with the valproate model of autism</article-title><trans-title-group xml:lang="ru"><trans-title>Активность ферментов, разрушающих внеклеточные нуклеотиды, в тканях крыс с вальпроатной моделью аутизма</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0002-0158-5971</contrib-id><name-alternatives><name xml:lang="en"><surname>Ivanova</surname><given-names>Daria V.</given-names></name><name xml:lang="ru"><surname>Иванова</surname><given-names>Дарья Викторовна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Assist., Depart. of Pharmacology</p></bio><bio xml:lang="ru"><p>асс., каф. фармакологии</p></bio><email>ivanovadv96@yandex.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0008-9564-8171</contrib-id><name-alternatives><name xml:lang="en"><surname>Khabirov</surname><given-names>Rinat A.</given-names></name><name xml:lang="ru"><surname>Хабиров</surname><given-names>Ринат Альбертович</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>M.D., Resident, Depart. of Internal Medicine</p></bio><bio xml:lang="ru"><p>ординатор, каф. внутренних болезней</p></bio><email>rinat.habirov.99@yandex.ru</email><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-9087-7927</contrib-id><name-alternatives><name xml:lang="en"><surname>Ziganshin</surname><given-names>Ayrat U.</given-names></name><name xml:lang="ru"><surname>Зиганшин</surname><given-names>Айрат Усманович</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>M.D., D. Sci. (Med.), Prof., Head of Depart., Dept. of Pharmacology</p></bio><bio xml:lang="ru"><p>докт. мед. наук, проф., зав. каф., каф. фармакологии</p></bio><email>ayrat.ziganshin@kazangmu.ru</email><xref ref-type="aff" rid="aff1"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">Kazan State Medical University</institution></aff><aff><institution xml:lang="ru">Казанский государственный медицинский университет</institution></aff></aff-alternatives><aff-alternatives id="aff2"><aff><institution xml:lang="en">Kazan (Volga Region) Federal University</institution></aff><aff><institution xml:lang="ru">Казанский (Приволжский) федеральный университет</institution></aff></aff-alternatives><pub-date date-type="preprint" iso-8601-date="2023-12-28" publication-format="electronic"><day>28</day><month>12</month><year>2023</year></pub-date><pub-date date-type="pub" iso-8601-date="2024-02-02" publication-format="electronic"><day>02</day><month>02</month><year>2024</year></pub-date><volume>105</volume><issue>1</issue><issue-title xml:lang="en"/><issue-title xml:lang="ru"/><fpage>84</fpage><lpage>89</lpage><history><date date-type="received" iso-8601-date="2023-10-19"><day>19</day><month>10</month><year>2023</year></date><date date-type="accepted" iso-8601-date="2023-12-28"><day>28</day><month>12</month><year>2023</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2024, Eco-Vector</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2024, Эко-Вектор</copyright-statement><copyright-year>2024</copyright-year><copyright-holder xml:lang="en">Eco-Vector</copyright-holder><copyright-holder xml:lang="ru">Эко-Вектор</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/" start_date="2027-02-02"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">http://creativecommons.org/licenses/by-nc-sa/4.0</ali:license_ref></license></permissions><self-uri xlink:href="https://kazanmedjournal.ru/kazanmedj/article/view/611074">https://kazanmedjournal.ru/kazanmedj/article/view/611074</self-uri><abstract xml:lang="en"><p><bold>BACKGROUND:</bold> Ectonucleotidases hydrolyze extracellular nucleotides and thus can control the effect of these substances on purinergic P1 and P2 receptors.</p> <p><bold>AIM:</bold> To evaluate the activity of ectonucleotidases in the smooth muscle tissues of internal organs of 9-month-old rats with the valproate model of autism using high-performance liquid chromatography.</p> <p><bold>MATERIAL AND METHODS:</bold> Autism was modeled in outbred Wistar rats by administering valproic acid (500 mg/kg) subcutaneously to pregnant females on days 12–13 of pregnancy. The born offspring were used in the study when the rats reached 270±8 days. Animals were guillotined under light ether anesthesia, the bladder, uterus, vas deferens, and duodenum were isolated, and smooth muscle tissue samples were prepared. Total ectonucleotidase activity was determined by incubating tissue samples with adenosine triphosphate (reaction substrate) for 10 minutes with further assessment of the content of the substrate and reaction products (adenosine diphosphate, adenosine monophosphate) in the incubate using high-performance liquid chromatography. Mathematical and statistical processing of the results was carried out using Microsoft Excel and IBM SPSS Statistics 26.0 software. Group comparisons were made using the nonparametric Mann–Whitney U test. Differences were considered significant at p &lt;0.05.</p> <p><bold>RESULTS:</bold> In rats with the valproate model of autism, the activity of ectonucleotidases in the smooth muscle tissues of the vas deferens (609.5±153.9) and uterus (232.7±2) was significantly lower than control values (2114.6±524.3, p=0.040; 539.6±63.5, p=0.010, respectively). In the duodenum (1808.4±184.5) and bladder (1021.3±280.7) we did not find a significant difference compared to the control values (2115.0±393.3, p=0.712; 2302.3±615.8, p=0.274, respectively). This study allows us to evaluate the possible contribution of purinergic transmission to the changes we found earlier in the contractile activity of smooth muscle tissue in rats with the valproate model of autism.</p> <p><bold>CONCLUSION:</bold> In 9-month-old rats with a model of autism, the activity of ectonucleotidases in the smooth muscle tissues of the reproductive organs is reduced; no such changes were found in the tissues of the intestines and bladder.</p></abstract><trans-abstract xml:lang="ru"><p><bold>Актуальность.</bold> Эктонуклеотидазы гидролизуют внеклеточные нуклеотиды и таким образом могут контролировать влияние этих веществ на пуринергические Р1- и Р2-рецепторы.</p> <p><bold>Цель.</bold> Оценить методом высокоэффективной жидкостной хроматографии активность эктонуклеотидаз в гладкомышечных тканях внутренних органов 9-месячных крыс с вальпроатной моделью аутизма.</p> <p><bold>Материал и методы исследования.</bold> Аутизм моделировали у крыс аутбредной линии Wistar введением беременным самкам на 12–13-й день беременности вальпроевой кислоты (500 мг/кг) однократно подкожно. Родившееся потомство использовали в исследовании по достижении крысами 270±8 дней. Животных гильотинировали под лёгким эфирным наркозом, выделяли мочевой пузырь, матку, семявыносящие протоки, двенадцатиперстную кишку и готовили образцы гладкомышечных тканей. Общую эктонуклеотидазную активность определяли путём инкубирования образцов тканей с аденозинтрифосфатом (субстрат реакции) в течение 10 мин с дальнейшей оценкой содержания субстрата и продуктов реакции (аденозиндифосфата, аденозинмонофосфата) в инкубате методом высокоэффективной жидкостной хроматографии. Математическую и статистическую обработку полученных результатов проводили с помощью программного обеспечения Microsoft Excel и IBM SPSS Statistics 26.0. Сравнение групп осуществляли с использованием непараметрического U-критерия Манна–Уитни. Достоверными считали различия при p &lt;0,05.</p> <p><bold>Результаты.</bold> У крыс с вальпроатной моделью аутизма активность эктонуклеотидаз гладкомышечных тканей семявыносящего протока (609,5±153,9) и матки (232,7±2) была достоверно ниже контрольных значений (2114,6±524,3, p=0,040; 539,6±63,5, p=0,010 соответственно). В двенадцатиперстной кишке (1808,4±184,5) и мочевом пузыре (1021,3±280,7) мы не обнаружили достоверной разницы в сравнении с контрольными значениями (2115,0±393,3, p=0,712; 2302,3±615,8, p=0,274 соответственно). Это исследование позволяет оценить возможный вклад пуринергической передачи в ранее найденные нами изменения в сократительной активности гладкомышечных тканей крыс с вальпроатной моделью аутизма.</p> <p><bold>Вывод.</bold> У крыс 9 мес с моделью аутизма снижена активность эктонуклеотидаз в гладкомышечных тканях репродуктивных органов; в тканях кишечника и мочевого пузыря таких изменений не обнаружено.</p></trans-abstract><kwd-group xml:lang="en"><kwd>autism</kwd><kwd>valproic model</kwd><kwd>rats</kwd><kwd>ectonucleotidases</kwd><kwd>purinoceptors</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>аутизм</kwd><kwd>вальпроевая модель</kwd><kwd>крысы</kwd><kwd>эктонуклеотидазы</kwd><kwd>пуринорецепторы</kwd></kwd-group><funding-group><award-group><funding-source><institution-wrap><institution xml:lang="ru">РНФ</institution></institution-wrap><institution-wrap><institution xml:lang="en">RSF</institution></institution-wrap></funding-source><award-id>проект № 22-25-00030</award-id></award-group></funding-group></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Zimmermann H. Ectonucleoside triphosphate diphosphohydrolases and ecto-5'-nucleotidase in purinergic signaling: How the field developed and where we are now. Purinergic Signal. 2021;17(1):117–125. DOI: 10.1007/s11302-020-09755-6.</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Robson SC, Sévigny J, Zimmermann H. The E-NTPDase family of ectonucleotidases: Structure function relationships and pathophysiological significance. Purinergic Signal. 2006;2(2):409–430. DOI: 10.1007/s11302-006-9003-5.</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Baqi Y. Ecto-nucleotidase inhibitors: Recent developments in drug discovery. Mini Rev Med Chem. 2015;15(1):21–33. DOI: 10.2174/1389557515666150219115141.</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Turner RJ, Guy TV, Geraghty NJ, Splitt A, Watson D, Brungs D, Carolan MG, Miller AA, de Leon JF, Aghmesheh M, Sluyter R. Low pretreatment CD4+CD8+ T cell ratios and CD39+CD73+CD19+ B cell proportions are associated with improved relapse-free survival in head and neck squamous cell carcinoma. Int J Mol Sci. 2023;24(16):12538. DOI: 10.3390/ijms241612538.</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Roberts V, Stagg J, Dwyer KM. The role of ectonucleotidases CD39 and CD73 and adenosine signaling in solid organ transplantation. Front Immunol. 2014;5:64. DOI: 10.3389/fimmu.2014.00064.</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Zlomuzica A, Burghoff S, Schrader J, Dere E. Superior working memory and behavioural habituation but diminished psychomotor coordination in mice lacking the ecto-5′-nucleotidase (CD73) gene. Purinergic Signal. 2013;9(2):175–182. DOI: 10.1007/s11302-012-9344-1.</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Aliagas E, Villar-Menéndez I, Sévigny J, Roca M, Romeu M, Ferrer I, Martín-Satué M, Barrachina M. Reduced striatal ecto-nucleotidase activity in schizophrenia patients supports the “adenosine hypothesis”. Purinergic Signal. 2013;9(4):599–608. DOI: 10.1007/s11302-013-9370-7.</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Zimmermann FF, Gaspary KV, Siebel AM, Leite CE, Kist LW, Bogo MR, Bonan CD. Analysis of extracellular nucleotide metabolism in adult zebrafish after embryological exposure to valproic acid. Mol Neurobiol. 2016;54(5):3542–3553. DOI: 10.1007/s12035-016-9917-z.</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Zhang Y, Xiang Z, Jia Y, Xue-Ling H, Wang L, Cui W. The Notch signaling pathway inhibitor Dapt alleviates autism-like behavior, autophagy and dendritic spine density abnormalities in a valproic acid-induced animal model of autism. Prog Neuropsychopharmacol Biol Psychiatry. 2019;94:109644. DOI: 10.1016/j.pnpbp.2019.109644.</mixed-citation></ref><ref id="B10"><label>10.</label><citation-alternatives><mixed-citation xml:lang="en">Semina II, Valeeva EV, Nikitin DO, Baichurina AZ, Nikitina AV, Shilovskaya EV, Kravtsova OA. Sex differences in rats in the valproate autism model: disorders in social behavior and changes in Drd1 gene expression in different brain structures. Zhurnal vysshey nervnoy deyatelnosti im IP Pavlova. 2022;72(6):862–879. (In Russ.) DOI: 10.31857/S0044467722060089.</mixed-citation><mixed-citation xml:lang="ru">Семина И.И., Валеева Е.В., Никитин Д.О., Байчурина А.З., Никитина А.В., Шиловская Е.В., Кравцова О.А. Половые различия у крыс в вальпроатной модели аутизма: нарушение социального поведения и изменение экспрессии гена Drd1 в различных структурах мозга. Журнал высшей нервной деятельности им. И.П. Павлова. 2022;72(6):862–879. DOI: 10.31857/S0044467722060089.</mixed-citation></citation-alternatives></ref><ref id="B11"><label>11.</label><citation-alternatives><mixed-citation xml:lang="en">Ivanova DV, Ziganshin AU. Evaluation of disorders of contractile activity of smooth muscle tissues in 9-month-old rats with a model of autism. Bulletin of Experimental Biology and Medicine. 2022;174(9):306–310. (In Russ.) DOI: 10.47056/0365-9615-2022-174-9-306-310.</mixed-citation><mixed-citation xml:lang="ru">Иванова Д.В., Зиганшин А.У. Оценка нарушений сократительной активности гладкомышечных тканей 9-месячных крыс с моделью аутизма. Бюллетень экспериментальной биологии и медицины. 2022;174(9):306–310. DOI: 10.47056/0365-9615-2022-174-9-306-310.</mixed-citation></citation-alternatives></ref><ref id="B12"><label>12.</label><citation-alternatives><mixed-citation xml:lang="en">Ivanova DV, Ziganshin AU. Comparative assessment of disorders contractions of the isolated uterus in 3- and 9-month-old rats with a model of autism. Bulletin of Experimental Biology and Medicine. 2023;175(3):321–325. (In Russ.) DOI: 10.47056/0365-9615-2023-175-3-321-325.</mixed-citation><mixed-citation xml:lang="ru">Иванова Д.В., Зиганшин А.У. Сравнительная оценка нарушений сокращений изолированной матки крыс с моделью аутизма в возрасте 3 и 9 мес. Бюллетень экспериментальной биологии и медицины. 2023;175(3):321–325. DOI: 10.47056/0365-9615-2023-175-3-321-325.</mixed-citation></citation-alternatives></ref><ref id="B13"><label>13.</label><citation-alternatives><mixed-citation xml:lang="en">Ziganshin AU, Ivanova DV. Carbachol-induced contractions of isolated intestine are increased in rats with experimental autism induced by valproic acid. Eksperimentalnaya i klinicheskaya farmakologiya. 2021;84(2):99–103. (In Russ.) DOI: 10.30906/0869-2092-2021-84-2-99-103.</mixed-citation><mixed-citation xml:lang="ru">Зиганшин А.У., Иванова Д.В. Вызванные карбахолином сокращения изолированной тонкой кишки возрастают у крыс с экспериментальным аутизмом, вызванным вальпроевой кислотой. Экспериментальная и клиническая фармакология. 2021;84(2):99–103. DOI: 10.30906/0869-2092-2021-84-2-99-103.</mixed-citation></citation-alternatives></ref><ref id="B14"><label>14.</label><mixed-citation>Hirsch MM, Deckmann I, Santos-Terra J, Staevie GZ, Fontes-Dutra M, Carello-Collar G, Körbes-Rockenbach M, Brum Schwingel G, Bauer-Negrini G, Rabelo B, Gonçalves MCB, Corrêa-Velloso J, Naaldijk Y, Castillo ARG, Schneider T, Bambini-Junior V, Ulrich H, Gottfried C. Effects of single-dose antipurinergic therapy on behavioral and molecular alterations in the valproic acid-induced animal model of autism. Neuropharmacology. 2020;(167):107930. DOI: 10.1016/j.neuropharm.2019.107930.</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>Ibi D, Fujiki Y, Koide N, Nakasai G, Takaba R, Hiramatsu M. Paternal valproic acid exposure in mice triggers behavioral alterations in offspring. Neurotoxicol Teratol. 2019;(76):106837. DOI: 10.1016/j.ntt.2019.106837.</mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation>Mirza R, Bhupesh S. A selective peroxisome proliferator-activated receptor-γ agonist benefited propionic acid induced autism-like behavioral phenotypes in rats by attenuation of neuroinflammation and oxidative stress. Chem Biol Interact. 2019;(311):108758. DOI: 10.1016/j.cbi.2019.108758.</mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation>Zheng W, Hu Y, Chen D, Li Y, Wang S. Improvement of a mouse model of valproic acid-induced autism. Nan Fang Yi Ke Da Xue Xue Bao. 2019;(39):718–723. DOI: 10.12122/j.issn.1673-4254.2019.06.14.</mixed-citation></ref><ref id="B18"><label>18.</label><citation-alternatives><mixed-citation xml:lang="en">Malyshev AV, Abbasova KR, Averina OA, Solovieva LN, Gedzun VR, Gulyaev MV, Dubynin VA. Fetal valproate syndrome as an experimental model of autism. Moscow University Biological Sciences Bulletin. 2015;16(3):8–12. (In Russ.) DOI: 10.3103/S0096392515030074.</mixed-citation><mixed-citation xml:lang="ru">Малышев А.В., Аббасова К.Р., Аверина О.А., Соловьёва Л.Н., Гедзун В.Р., Гуляев М.В., Дубынин В.А. Экспериментальная модель аутистического расстройства: индуцированный фетальный вальпроатный синдром. Вестник Московского университета. Серия 16: Биология. 2015;16(3):8–12. DOI: 10.3103/S0096392515030074.</mixed-citation></citation-alternatives></ref></ref-list></back></article>
